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A B S T R A C T
Background
The long-acting bronchodilator tiotropium and single inhaler combination therapy of inhaled corticosteroids and long-acting beta2-
agonists are both commonly used for maintenance treatment of chronic obstructive pulmonary disease. Combining these treatments,
which have different mechanisms of action, may be more effective than the individual components. However, the benefits and risks of
using tiotropium and combination therapy together for the treatment of chronic obstructive pulmonary disease are unclear.
Objectives
To assess the relative effects of inhaled corticosteroid and long-acting beta2-agonist combination therapy in addition to tiotropium
compared to tiotropium or combination therapy alone in patients with chronic obstructive pulmonary disease.
Search methods
We searched the Cochrane Airways Group Specialised Register of trials (July 2010) and reference lists of articles.
Selection criteria
We included parallel, randomised controlled trials of three months or longer, comparing inhaled corticosteroid and long-acting beta2-
agonists combination therapy in addition to inhaled tiotropium against tiotropium alone or combination therapy alone.
Data collection and analysis
We independently assessed trials for inclusion and then extracted data on trial quality and outcome results. We contacted study authors
for additional information. We collected information on adverse effects from the trials.
Main results
Three trials (1021 patients) were included comparing tiotropium in addition to inhaled corticosteroid and long-acting beta2-agonist
combination therapy to tiotropium alone. The duration, type of combination treatment and definition of outcomes varied. The limited
data led to wide confidence intervals and there was no significant statistical difference in mortality, participants with one or more
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hospitalisations, episodes of pneumonia or adverse events. The results on exacerbations were heterogeneous and were not combined. The
mean health-related quality of life and lung function were significantly different when combination therapy was added to tiotropium,
although the size of the average benefits of additional combination therapy were small, St George’s Respiratory Questionnaire (MD -
2.49; 95% CI -4.04 to -0.94) and forced expiratory volume in one second (MD 0.06 L; 95% CI 0.04 to 0.08).
One trial (60 patients) compared tiotropium plus combination therapy to combination therapy alone. The results from the trial were
insufficient to draw firm conclusions for this comparison.
Authors’ conclusions
To date there is uncertainty regarding the long-term benefits and risks of treatment with tiotropium in addition to inhaled corticosteroid
and long-acting beta2-agonist combination therapy onmortality, hospitalisation, exacerbations of COPDand pneumonia. The addition
of combination treatment to tiotropium has shown improvements in average health-related quality of life and lung function.
P L A I N L A N G U A G E S U M M A R Y
Is it better to take tiotropium plus combination inhalers than tiotropium or combination inhalers alone for the treatment of
chronic obstructive pulmonary disease?
Chronic obstructive pulmonary disease (COPD) is a lung disease which includes the conditions chronic bronchitis and/or emphysema.
COPD is characterised by blockage or narrowing of the airways. The symptoms include breathlessness and chronic cough. COPD is
an irreversible disease that is usually brought on by airway irritants, such as smoking or inhaled dust.
Inhalers with bronchodilators and/or anti-inflammatory agents are commonly used to ease symptoms and minimise the long-term
decline in health caused by COPD. Examples of these treatments are tiotropium which is a bronchodilator and combination inhalers
which contain another type of bronchodilator (long-acting beta-agonists) together with anti-inflammatory agents (steroids). These
treatments work in different ways and therefore might be more beneficial if used together.
This review found three studies, involving 1021 patients, comparing the long-term efficacy and side effects of combining tiotropium
with combination inhalers for treating COPD. In these studies there were not enough patients and the studies were too different from
each other for us to be able to draw any firm conclusions as to whether combining tiotropium with combination inhalers is better or
worse than using either drug alone for mortality, hospitalisation and pneumonia. The addition of combination inhalers to tiotropium
did show small benefits in quality of life and lung function tests.
In order to better understand the effect of treatment with tiotropium and combination inhaler more long-term studies need to be done.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Tiotropium plus LABA/ICS combination compared to Tiotropium plus placebo for chronic obstructive pulmonary disease
Patient or population: patients with chronic obstructive pulmonary disease
Settings:
Intervention: Tiotropium plus LABA/ICS combination
Comparison: Tiotropium plus placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Tiotropium plus placebo Tiotropium plus LABA/
ICS combination
Mortality (all cause)
Follow-up: 3 to 12
months
8 per 1000 15 per 1000
(5 to 48)
OR 1.88
(0.57 to 6.23)
1021
(2 studies)
⊕⊕©©
low1,2
Hospital admission (all
causes)
Follow-up: 3 to 12
months
103 per 1000 88 per 1000
(57 to 132)
OR 0.84
(0.53 to 1.33)
961
(2 studies)
⊕⊕©©
low1,2
Hospital admission (ex-
acerbation)
Follow-up: 3 to 12
months
78 per 1000 53 per 1000
(32 to 87)
OR 0.66
(0.39 to 1.13)
961
(2 studies)
⊕⊕©©
low1,2
Exacerbation See comment See comment Not estimable 961
(2 studies)
See comment Results not combined as
there was too much het-
erogeneity between the
results of the two included
studies
3
C
o
m
b
in
a
tio
n
in
h
a
le
d
ste
ro
id
a
n
d
lo
n
g
-a
c
tin
g
b
e
ta
2
-a
g
o
n
ist
in
a
d
d
itio
n
to
tio
tro
p
iu
m
v
e
rsu
s
tio
tro
p
iu
m
o
r
c
o
m
b
in
a
tio
n
a
lo
n
e
fo
r
c
h
ro
n
ic
o
b
stru
c
tiv
e
p
u
lm
o
n
a
r
y
d
ise
a
se
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
1
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Pneumonia
Follow-up: 3 to 12
months
6 per 1000 8 per 1000
(2 to 35)
OR 1.35
(0.31 to 5.99)
961
(2 studies)
⊕⊕©©
low1,2
One trial only reported
pneumonia leading tome-
chanical ventilation or
death
Quality of life SGRQ
scale - Quality of life 3-5
months mean difference
+ 1 yr SE
The mean Quality of life
SGRQ scale - Quality of
life 3-5 months mean dif-
ference + 1 yr SE in the
intervention groups was
2.49 lower
(4.04 to 0.94 lower)
961
(2 studies)
⊕⊕©©
low1,2
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; OR: odds ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Unequal loss to follow-up
2 Wide confidence intervals
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B A C K G R O U N D
Description of the condition
Chronic obstructive pulmonary disease (COPD) is a general term
referring to chronic bronchitis and emphysema, or both. COPD
occurs when airflow to the lungs is restricted because of narrow-
ing of the airways. Symptoms include cough, breathlessness and
reduced exercise capacity. The Global Initiative for Chronic Ob-
structive Lung Disease (GOLD) guidelines describe COPD as a
preventable and treatable condition that is not fully reversible.
Worldwide, the main cause of COPD is tobacco smoking, how-
ever air pollution is also a risk factor. The prevalence, morbidity
and mortality of the disease vary across populations and cause a
substantial economic and social burden.
There are a number of commonly used pharmacological treat-
ments in COPD management that are used to relieve symptoms,
improve exercise tolerance and quality of life, reduce mortality,
and prevent and treat exacerbations. COPD exacerbations impair
patients’ quality of life and a large part of the economic burden of
COPD is attributed to the cost of managing exacerbations, par-
ticularly those resulting in use of acute care services or hospital-
isations (Hutchinson 2010). Appropriate pharmacological man-
agement of the disease is therefore important to reduce and pre-
vent exacerbations. COPD management tends to begin with one
treatment and additional therapies are introduced as necessary to
control symptoms (GOLD). Self-management education and re-
habilitation can accompany these pharmacological interventions
(Effing 2007; Lacasse 2006).
Description of the intervention
The first pharmacological step in treating COPD is the use of
short-acting bronchodilators for symptom control when needed.
These include short-acting beta2-agonists (SABA) and the short-
acting anticholinergic ipratropium. For managing persistent
COPD symptoms, long-acting bronchodilators can be introduced
(GOLD). Regular treatment with long-acting bronchodilators is
both more efficient and convenient than treatment with regu-
lar short-acting bronchodilators (Beeh 2010). Long-acting bron-
chodilators include long-acting beta2-agonists (LABA) and the
long-acting anticholinergic agent tiotropium. Tiotropium bro-
mide has gained widespread acceptance as a once daily mainte-
nance therapy in COPD (Barr 2005; GOLD). Tiotropium re-
duces COPD exacerbations and related hospitalisations compared
to ipratropium (Barr 2005). Most long-acting beta2-agonists are
taken twice daily. They improve lung function compared to ipra-
tropium, but there is little difference in improving COPD symp-
toms and exercise tolerance (Appleton 2006). For symptomatic
patients with severe or very severe COPD (FEV1 < 50% pre-
dicted) and with repeated exacerbations, GOLD recommends the
addition of inhaled corticosteroids (ICS) to bronchodilator treat-
ment. Inhaled corticosteroids are licensed as combination inhalers
with long-acting beta2-agonists. The most common combina-
tions of inhaled corticosteroid and long-acting beta2-agonist in
combination inhalers are fluticasone and salmeterol and budes-
onide and formoterol. Combination therapy reduces exacerbation
rates and all-cause mortality compared to inhaled corticosteroid
alone (Nannini 2007). Also compared to long-acting beta2-ago-
nists alone, combination therapy is more effective in reducing ex-
acerbation rates, but there is no significant difference in mortality
(Nannini 2007b). The benefits of combination inhalers should be
viewed against the possible increased risk of pneumonia (Nannini
2007b). The potential risks or benefits of treatmentwith combina-
tion inhaler compared to tiotropium are uncertain (Welsh 2010),
as are the risks or benefits of treatment with combination inhaler
in addition to tiotropium, which will be explored in this review.
How the intervention might work
Tiotropium
Tiotropium is a long-acting anticholinergic agent that targets
bronchospasm in COPD by relaxing airway smooth muscle.
Tiotropium is structurally related to ipratropium, a short-acting
anticholinergic agent that binds to M1, M2 and M3 muscarinic
receptors which in turn open the bronchi (Barr 2005). Although
tiotropium binds to the same receptors as ipratropium, it has a dif-
ferent kinetic selectivity. Tiotropium dissociates slowly from M1
and M3 receptors giving a bronchodilator effect lasting over 24
hours, but rapidly from M2 receptors. It appears that M2 recep-
tors are feedback inhibitory receptors, and blocking them (as is the
case for ipratropium) releases acetylcholine rather than reducing it
as desired (Barr 2005). Benefits of tiotropium, in comparison with
placebo, include reduced COPD exacerbations and exacerbation-
related hospitalisations, and improved health-related quality of life
and symptom scores among patients with moderate and severe
disease (Barr 2005). Anticholinergic side effects can occur with
tiotropium and include dry mouth, constipation and tachycardia.
Combination inhalers
Inhaled beta2-agonists activate beta2-receptors in the smoothmus-
cle of the airway, releasing adenylate cyclase and increasing intra-
cellular cAMP (cyclic adenosine monophosphate) which leads to
a cascade of reactions resulting in bronchodilation. Beta2-agonists
may act through other mechanisms such as respiratory muscle
function or mucociliary clearance, because patients have shown
improvement in symptoms whilst showing no improvement in
lung function tests. Beta2-agonists are particularly useful because
they reverse bronchoconstriction regardless of the initial cause of
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the bronchoconstriction. Side effects include muscle tremors, ner-
vousness and occasional insomnia but, as with all inhaled medi-
cations, systemic side effects are minimised by giving a compar-
atively low dose directly to the lungs. Inhaled corticosteroids are
anti-inflammatory drugs. They reduce the rate of exacerbations
and the rate of decline in quality of life compared to placebo, with-
out effect on overall mortality or the long-term decline in FEV1
(GOLD; Yang 2007). Combination inhalers including inhaled
corticosteroids and long-acting beta2 -agonists reduce exacerbation
rates and all-cause mortality, and improve lung function and qual-
ity of life compared to placebo (Nannini 2007a). These effects
are thought to be greater for combination inhalers than from the
component preparations (GOLD). Inhaled corticosteroids, alone
or in combinationwith beta2 -agonists, potentially increase the risk
of pneumonia (GOLD; Yang 2007).
Why it is important to do this review
Although both tiotropium and combination therapy inhalers are
recommended for treatment of COPD, the relative effects of com-
bination therapy compared to tiotropiumonpatients withCOPD
are unclear (Welsh 2010). However, it has been hypothesised that
combining bronchodilators with different mechanisms and dura-
tion of action may be more effective than the individual compo-
nents in improving bronchodilation without increasing side ef-
fects. For example a combination of salbutamol and ipratropium
has been shown to improve FEV1 without an associated increase
in tachyphylaxis (GOLD). Recent trials have been published on
adding tiotropium to combined inhalers, and this review is neces-
sary to show whether there is a benefit from this treatment regime
compared to tiotropium or combination therapy alone.
O B J E C T I V E S
To assess the relative effects of the following treatments onmarkers
of exacerbations, symptoms, quality of life, and lung function in
patients with COPD:
• Tiotropium plus LABA/ICS versus tiotropium
• Tiotropium plus LABA/ICS versus LABA/ICS
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included only randomised controlled trials with a parallel
group design of at least three months’ duration. Studies were not
excluded on the basis of blinding.
Types of participants
Populations with a diagnosis of COPD. We included only studies
that used an external set of criteria to screen participants for this
condition (e.g. GOLD; ATS; BTS; TSANZ).
Types of interventions
Inhaled combination corticosteroid and long-acting beta2-ago-
nist (such as fluticasone/salmeterol, budesonide/formoterol, be-
clomethasone/formoterol) and tiotropium bromide versus
1. Inhaled tiotropium bromide alone
2. Inhaled combination corticosteroid and long-acting beta2-
agonist
Types of outcome measures
Primary outcomes
1. Mortality (all cause)
2. Hospital admissions; all cause and due to exacerbations
3. Exacerbations; all cause, requiring short burst oral
corticosteroids or antibiotics as defined by agreed criteria
4. Pneumonia
5. Health-related quality of life (measured with a validated
scale for COPD, e.g. St George’s Respiratory Questionnaire,
Chronic Respiratory Disease Questionnaire)
Secondary outcomes
1. Symptoms
2. Forced expiratory volume in one second (FEV1)
3. Non-fatal serious adverse events
4. Adverse events
5. Side effects
6. Withdrawals
Search methods for identification of studies
Electronic searches
We identified trials using theCochrane Airways Group Specialised
Register of trials, which is derived from systematic searches of
bibliographic databases including the Cochrane Central Regis-
ter of Controlled Trials (CENTRAL), MEDLINE, EMBASE,
CINAHL, AMED, and PsycINFO, and handsearching of respira-
tory journals andmeeting abstracts (please see the Airways Group
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Module for further details). All records in the Specialised Register
coded as ’COPD’ were searched using the following terms:
(tiotropium or spiriva)
AND
(((budesonide or fluticasone or beclomethasone or mometasone
or steroid* or corticosteroid*) and (*formoterol or salmeterol or
indacterol or (beta* and agonist*))) or (symbicort or viani or sere-
tide or advair or foster or fostair or inuvair or fostex or kantos or
combination*))
The search was conducted in July 2010.
Searching other resources
Wereviewed reference lists of all primary studies and review articles
for additional references. We contacted authors of identified trials
and we asked them to identify other published or unpublished
studies.
Data collection and analysis
Selection of studies
Two review authors (CK and CJC) screened the titles and ab-
stracts of citations retrieved through literature searches and ob-
tained those deemed to be potentially relevant. Each reference was
assigned to a study identifier and assessed against the inclusion
criteria of this protocol.
Data extraction and management
We extracted information from each study for the following char-
acteristics:
1. Design (design, total duration study and run in, number of
study centres and location, withdrawals, date of study).
2. Participants (N, mean age, age range, gender, COPD
severity, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria, exclusion criteria).
3. Interventions (run-in, intervention treatment and inhaler
type, control treatment and inhaler type).
4. Outcomes (primary and secondary outcomes specified and
collected, time points reported).
Two authors (CK and CJC) extracted data from the studies into
data collection forms. Any discrepancies in the data were discussed
and resolved between the authors. The data were then transferred
from data collection forms into Review Manager 5.
Assessment of risk of bias in included studies
We assessed all included studies for the risk of bias according to rec-
ommendations outlined in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2009) for the following items:
1. Allocation sequence generation
2. Concealment of allocation
3. Blinding of participants and investigators
4. Incomplete outcome data
5. Selective outcome reporting
Other sources of bias have been noted. We graded each potential
source of bias as yes, no or unclear, relating towhether the potential
for bias was low, high or unknown respectively.
Measures of treatment effect
Weanalysed dichotomous variables (such asmortality, participants
with at least one hospital admission etc.) using the Mantel-Haen-
szel fixed odds ratio with 95% confidence intervals, unless events
were rare, in which case we employed the Peto odds ratio (since
this does not require a continuity correction for zero cells).
We analysed continuous outcome data (such as quality of life and
FEV1) as fixed-effect mean differences with 95% confidence in-
tervals as the same scale was used. Where treatment effects were
reported as a mean difference with 95% confidence intervals, we
entered the mean difference and standard errors calculated from
95% confidence intervals and analysed the data using the generic
inverse variance (GIV) tool in Review Manager 5. For data which
were not reported as the number of participants experiencing an
event, we entered the natural log of reported rate ratios along with
the standard error calculated from 95% confidence intervals into
Review Manager 5 using the GIV function.
Unit of analysis issues
We analysed dichotomous data using participants as the unit of
analysis (rather than events) to avoid counting the same participant
more than once.
Dealing with missing data
We contacted investigators and study sponsors in order to verify
key study characteristics and obtain missing numerical outcome
data.
Assessment of heterogeneity
We assessed the amount of statistical variation between the study
results with the I2 measurement.
Assessment of reporting biases
We minimised reporting bias from non-publication of studies or
selective outcome reporting by using a broad search strategy, con-
tacting study authors directly and checking references of included
studies. We planned to assess reporting bias by visual inspection
of funnel plots.
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Data synthesis
We combined dichotomous data using Mantel-Haenszel odds ra-
tios with a fixed-effect model and compared this to the random-
effects model. We combined rate ratios and hazard ratios using
generic inverse variance using a fixed-effect model and compared
to the random-effects model. We planned to calculate the num-
bers needed to treat for an additional beneficial outcome from
the pooled odds ratio and its confidence interval, and apply to
appropriate levels of baseline risk. We have presented the findings
of our primary outcomes in Summary of findings for the main
comparison generated using GradePro software.
Subgroup analysis and investigation of heterogeneity
We planned to subgroup studies according to:
1. Type of combination therapy
2. Severity of disease at baseline
Sensitivity analysis
We intended to assess the sensitivity of our primary outcomes to
degree of bias by comparing the overall results with those exclu-
sively from trials assessed as being at low risk of bias.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
Results of the search
The initial search identified 101 references. Of these we identi-
fied 24 as potentially relevant, which we obtained in full text for
further assessment. Fourteen of these were eligible for inclusion
and belonged to three studies (Aaron 2007; Cazzola 2007; Welte
2009) (see Characteristics of included studies). Peer review iden-
tified one further potentially eligible study and is noted in Studies
awaiting classification (Fang 2008).
Included studies
Study design: Two of the studies had a treatment duration of
three months (Cazzola 2007; Welte 2009) and the third was a one
year study (Aaron 2007). Both Aaron 2007 and Welte 2009 were
multi-centre studies. The centres for the Aaron 2007 study were
all located in Canada, whereas the Welte 2009 study centres were
spread across nine different countries.
Sample size: There were 1051 participants randomised to the
relevant treatments in the included studies; tiotropium + LABA/
ICS (504), tiotropium (517), andLABA/ICS (30). These included
two larger studies; Welte 2009 (n = 660) and Aaron 2007 (n =
301), and one smaller; Cazzola 2007 (n = 90).
Participants: The mean age of participants varied from 62 to 68
years. The gender distribution varied from 56% males in Aaron
2007 to 89% in Cazzola 2007. The severity of COPD varied from
moderate to very severe according to GOLD guideline definitions
ofCOPD.However, the baseline lung function for the participants
was similar in the included studies with the mean FEV1 predicted
averaging 38% to 39%.
Interventions: All included studies used 18 µg of tiotropium
(Handihaler), one inhalation daily. In Welte 2009 the LABA/
ICS combination used was budesonide/formoterol 320/9 µg (Tur-
buhaler), one inhalation twice daily. Both Aaron 2007 andCazzola
2007 usedfluticasone/salmeterol (Diskus). InAaron 2007 the dose
used was 250/25 µg, two inhalations twice daily, and in Cazzola
2007 the concentration was 500/50 µg, one inhalation twice daily.
Permitted co-treatment: In Aaron 2007 participants were in-
structed to use inhaled albuterol when necessary to relieve symp-
toms. Respiratory medications such as oxygen, antileukotrienes,
and methylxanthines, were continued in all patient groups. In
Welte 2009 terbutaline was used as needed for symptom relief
in both treatment groups. Cazzola 2007 permitted supplemental
salbutamol for relief of symptoms, which was monitored through-
out the study. Stable regimens of theophylline were also allowed.
Outcomes: The primary outcome for Aaron 2007 was the pro-
portion of patients suffering one or more COPD exacerbations.
Both Welte 2009 and Cazzola 2007 studied the change in FEV1
from randomisation to the end of the study (three months) as their
primary outcome.
Funding: The Welte 2009 study was sponsored by AstraZeneca,
the producer of the LABA/ICS combination budesonide/for-
moterol (Symbicort Turbuhaler) used in the trial. The Aaron 2007
study was funded by the Canadian Institutes of Health Research
and the Ontario Thoracic Society. We were not able to obtain
information about funding for the Cazzola 2007 study.
Excluded studies
A total of eight studies failed to meet the eligibility criteria for
the review (see Characteristics of excluded studies). Four of these
compared tiotropium alone with combination therapy (LABA/
ICS) (Ando 2008; Bateman 2008; Golabi 2006; Hara 2007) and
one study compared tiotropium with LABA alone (Petroianni
2008). The remaining three studies were all shorter than three
months (Biscione 2009; Perng 2006), and one of these was also of
cross-over design (Singh 2008).
Risk of bias in included studies
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An assessment of the risk of bias is presented in the Characteristics
of included studies table, and an overview of the findings is shown
in Figure 1.
Figure 1. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
Aaron 2007 and Welte 2009 reported adequate sequence genera-
tion and allocation concealment. Details forWelte 2009 were sup-
plied on request. For both studies randomisation was computer-
generated through central allocation and both research staff and
patients were blinded to the treatment assignment until the end of
study. Cazzola 2007 did not report full details regarding sequence
generation and allocation concealment in the study report.
Blinding
The blinding in Aaron 2007 and Welte 2009 was adequate.
Cazzola 2007 did not report full details of blinding procedures. In
Aaron 2007, the different inhalers containing placebo, salmeterol,
and fluticasone/salmeterol were identical in taste and appearance,
and theywere enclosed in identical tamper-proof blinding devices.
Themedication canisterswithin the blinding devices were stripped
of any identifying labelling. Clinical data for suspected exacerba-
tions were reviewed by a blinded committee judging whether the
data met the study definition of COPD exacerbation. Blinding of
patients was not broken for patients who prematurely discontin-
ued treatment with study medications, and the statistician who
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performed the analysis was initially blinded to patient group as-
signments. InWelte 2009, treatment assignment was concealed as
active and placebo inhalers were of identical appearance and both
clinicians and patients were blinded to treatment until completion
of the study.
Incomplete outcome data
Cazzola 2007 andWelte 2009 did not suffer from incomplete out-
come data. Aaron 2007 suffered from high and unevenwithdrawal
rates in the different study groups (74 patients (47%) withdrew
from the tiotropium + placebo group and 37 patients (26%) on
tiotropium + LABA/ICS). High withdrawal rates are common in
COPD trials over six months in length.
Formost patients, datawere recorded throughout the one-year trial
period regardless of whether patients discontinued treatment with
study medications. The rate of patients who stopped therapy and
did not complete the trial, however, was still relatively large and
unevenly distributed between the intervention groups (30 patients
(19%) tiotropium + placebo and 15 patients (10%) tiotropium +
LABA/ICS).Mortality data were obtained for all participants with
the exception of 2/145 (1.4%) on tiotropium + LABA/ICS and 4/
156 (2.6%) on tiotropium + placebo who withdrew and declined
further study.
Selective reporting
All three trials adequately reported outcome data for the primary
and secondary outcomes that they had pre-specified in the study
record.
Effects of interventions
See: Summary of findings for themain comparisonTiotropium
plus LABA/ICS combination compared to Tiotropium plus
placebo for chronic obstructive pulmonary disease
Because of the low number of eligible studies for the two compar-
isons (tiotropium + LABA/ICS versus tiotropium alone or versus
LABA/ICS alone), no subgroup analysis of disease severity or type
of combination therapy were possible.
Tiotropium plus LABA/ICS versus tiotropium plus
placebo
Two authors (CK and CJC) independently extracted and anal-
ysed results for all data. Dichotomous data including mortality,
exacerbations, pneumonia, adverse events and withdrawals were
analysed as end of study measurements as this was the only time
point for which these data were available. Continuous data were
analysed at three months for Cazzola 2007 and Welte 2009 (end
of study) and at both five months (20 weeks) and one year for
Aaron 2007.
Primary outcome: mortality (all causes)
Mortality data were available from two trials involving 1021 par-
ticipants, which reportedmortality as a secondary outcome (Aaron
2007; Welte 2009). The third study, Cazzola 2007 (60 partici-
pants), reported zero serious adverse events and therefore we as-
sumed there were no mortalities during the study. Taken together,
there was a greater number of deaths in the tiotropium + LABA/
ICS group (7/504) than in the tiotropium + placebo group (4/
517), however, there was no statistically significant difference in
mortality between the groups (Peto odds ratio (OR) 1.88; 95%
confidence interval (CI) 0.57 to 6.23) as shown in Figure 2. The
number of withdrawals from each of the arms in Aaron 2007,
which adds most weight to the comparison, was six times larger
than the number of deaths for participants on tiotropium+LABA/
ICS and 19 times larger for participants on tiotropium + placebo.
This uncertainty about the results is not reflected in the confidence
interval for the odds ratio.
Figure 2. Forest plot of comparison: 1 tiotropium + LABA/ICS combination vs tiotropium + placebo,
outcome: 1.1 Mortality (all cause).
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Primary outcome: hospital admissions (all cause)
Data regarding all cause hospital admissions were available from
two trials involving 961 participants. The data were kindly sup-
plied by Aaron 2007 and by AstraZeneca (for Welte 2009) on
request. The number of patients admitted to hospital from Welte
2009 did not include any due to exacerbation, as the sponsors had
recorded hospitalisations for COPD separately from other causes
and were not able to provide data on the overlap between these
two groups. Overall there were fewer patients admitted to hos-
pital in the tiotropium + LABA/ICS group (41/474) than in the
tiotropium + placebo group (50/487), however, there was no sta-
tistically significant difference between the groups when analysed
as dichotomous data (OR 0.84; 95% CI 0.53 to 1.33), as shown
in Figure 3.
Figure 3. Forest plot of comparison: 1 tiotropium + LABA/ICS combination vs tiotropium + placebo,
outcome: 1.2 Hospital admission (all causes).
However, as presented in the paper by Aaron 2007, when analysed
as a rate ratio the number of hospitalisations for any cause was
significantly lower among patients on tiotropium+LABA/ICS (41
hospitalisations/ 137.1 patient years) compared to patients treated
with tiotropium alone (62 hospitalisations/ 138.0 patient years),
(RR 0.67; 95% CI 0.45 to 0.99). Welte 2009 did not report rate
ratios of hospital admissions.
Primary outcome: hospital admissions (exacerbations)
Data regarding hospital admissions due to exacerbations were
available from two trials involving 961 participants. The data were
kindly supplied by Aaron 2007 and by AstraZeneca (for Welte
2009) on request. The number of patients admitted to hospi-
tal due to exacerbations were higher in the tiotropium + placebo
group (38/487) than in the tiotropium + LABA/ICS group (25/
474) (OR 0.66; 95% CI 0.39 to 1.13; Figure 4), although the
difference was not statistically significant for the pooled result or
the result from individual studies.
Figure 4. Forest plot of comparison: 1 tiotropium + LABA/ICS combination vs tiotropium + placebo,
outcome: 1.3 Hospital admission (exacerbation).
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Similarly to all-cause hospital admissions, Aaron 2007 showed
that when analysed as rate ratio there was a statistically signifi-
cant reduction in hospitalisation rates due to exacerbation among
patients on tiotropium + LABA/ICS (26 hospitalisations/ 137.1
patient years) compared to patients treated with tiotropium alone
(49 hospitalisations/ 138.0 patient years), (rate ratio 0.53; 95%CI
0.33 to 0.86). Welte 2009 also reported significantly lower rates of
hospitalisations/ emergency room visits for exacerbations among
patients treated with tiotropium + LABA/ICS (0.028 hospitali-
sations/ patient/ 3 months) compared to patients on tiotropium
alone (0.080 hospitalisations/ patient/ 3 months), (rate ratio 0.35;
95% CI 0.16 to 0.78).
Primary outcome: exacerbations
Aaron 2007 andWelte 2009 reported the number of patients that
experienced exacerbations (961 patients). Cazzola 2007 withdrew
patients experiencing exacerbations during the study period with-
out reporting the number of withdrawals due to exacerbation. In
Aaron 2007 exacerbation was defined as a sustained worsening
of the patient’s respiratory condition necessitating short-term use
of either oral or intravenous steroids, oral or intravenous antibi-
otics, or both therapies. In Welte 2009 exacerbation was defined
as worsening of COPD leading to treatment with systemic cor-
ticosteroids (oral or parenteral) and/or hospitalisation/emergency
room visits. In both studies fewer patients on tiotropium + LABA/
ICS had one or more exacerbations compared to the group treated
with tiotropium + placebo. In theWelte 2009 study the difference
was statistically significant (OR 0.36; 95% CI 0.22 to 0.60) with
a baseline risk of 0.18. The result from Aaron 2007 did not reach
statistical significance (OR 0.89; 95% CI 0.56 to 1.41) (baseline
risk 0.63). See Figure 5.
Figure 5. Forest plot of comparison: 1 tiotropium + LABA/ICS combination vs tiotropium + placebo,
outcome: 1.4 Exacerbation.
These results were consistent with the reported analysis of the in-
dividual study data as rate ratios. Welte 2009 showed significantly
fewer exacerbations in the group treated with tiotropium + LABA/
ICS (0.124 exacerbations/ patient/ 3 months) compared to the
group treated with tiotropium + placebo (0.326 exacerbations/
patient/ 3months), (OR 0.38; 95%CI 0.25 to 0.57). Aaron 2007
showed no significant difference in the number of exacerbations
between the two groups; tiotropium + LABA/ICS (188 exacerba-
tions/ 137.1 patient years), tiotropium + placebo (222 exacerba-
tions/ 138.0 patient years), (OR 0.85; 95% CI 0.65 to 1.11). We
did not pool the results because of considerable statistical hetero-
geneity across the studies (I2 = 85%).
Primary outcome: pneumonia
Aaron 2007 and Welte 2009 (961 patients) reported the num-
ber of patients suffering from pneumonia during the trials al-
though Aaron 2007 reported only the cases of pneumonia lead-
ing to mechanical ventilation or death. The number of events was
low and there was no statistically significant difference between
the tiotropium + LABA/ICS group and the tiotropium + placebo
group (Peto OR 1.35; 95% CI 0.31 to 5.99) as shown in Figure
6.
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Figure 6. Forest plot of comparison: 1 tiotropium + LABA/ICS combination vs tiotropium + placebo,
outcome: 1.5 Pneumonia.
Primary outcome: quality of life
Both Aaron 2007 and Welte 2009 studied changes in health-re-
lated quality of life (961 patients) using the St George’s Respira-
tory Questionnaire (SGRQ). We extracted and analysed the mean
change in health-related quality of life at three months (end of
study) for Welte 2009 and five months (20 weeks) (reported time
point closest to three months, data kindly supplied on request)
and one year for Aaron 2007. Standard errors and standard devi-
ations were not available for the mean difference at five months
for Aaron 2007. We assumed that these values were relatively con-
stant between fivemonths and one year, and imputed the standard
error for the mean difference at one year. At three to five months
the combination of tiotropium + LABA/ICS had a significantly
larger positive effect on the quality of life compared to tiotropium
+ placebo (MD -2.49; 95% CI -4.04 to -0.94), as shown in Figure
7. This was below the threshold of four units for clinically signif-
icant difference (SGRQ-C manual 2008). However, Welte 2009
reported the percentage of patients with improvements in SGRQ
score of more than four units, which was significantly higher in the
tiotropium + LABA/ICS group (49.5%) than in the tiotropium
+ placebo group (40.0%) (P = 0.016). The percentage of pa-
tients with a deterioration in SGRQ score of more than four units
were similar in the two groups (tiotropium + LABA/ICS 27.6%,
tiotropium + placebo group 29.7%) (Welte 2009).
Figure 7. Forest plot of comparison: 1 tiotropium plus LABA/ICS combination versus tiotropium plus
placebo, outcome: 1.6 Quality of life SGRQ scale.
Secondary outcome: symptoms
Welte 2009 was the only included study reporting changes in
COPD symptom scores for breathlessness (MD -0.142; 95% CI
-0.214 to -0.069), night awakening (MD -0.157; 95% CI -0.222
to -0.092), chest tightness (MD -0.142; 95%CI -0.212 to -0.072)
and cough (MD -0.161; 95% CI -0.238 to -0.084); 660 patients.
The scores for all symptoms were in favour of the tiotropium +
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LABA/ICS group compared to the tiotropium + placebo group (P
< 0.001).
Secondary outcome: forced expiratory volume in one
second (FEV1)
Changes in FEV1 over the treatment period weremeasured and re-
ported in all three included studies (1021 patients). Tiotropium in
combination with LABA/ICS improved FEV1 significantly com-
pared to tiotropium + placebo (MD 0.06; 95%CI 0.04 to 0.08) at
three (Cazzola 2007, Welte 2009) and five months (Aaron 2007).
This was below the threshold of 100 to 140 mL which is consid-
ered to be a clinically important increase (Cazzola 2008). FEV1
data at five months were kindly supplied on request by Aaron
2007. The standard error of the change from baseline in FEV1 for
Welte 2009 was calculated from the reported P value < 0.001.
Secondary outcome: serious adverse events (non-fatal)
In the three included studies (1021 patients) there were fewer pa-
tients suffering non-fatal serious adverse events in the tiotropium
+ LABA/ICS group (12/504) than in patients on tiotropium +
placebo (20/517) (OR 0.60; 95% CI 0.29 to 1.25), although the
difference was not statistically significant.
Secondary outcome: adverse events
In the three included studies (1021 patients) there was a slightly
larger number of patients suffering adverse events on tiotropium
+ LABA/ICS (140/504) than on patients on tiotropium + placebo
(132/517) (OR 1.12; 95% CI 0.85 to 1.49), again the difference
was not statistically significant.
Secondary outcome: side effects
Side effects were not reported in any of the included studies.
Secondary outcome: withdrawal
All three studies (1021 patients) reported the withdrawals from the
study.Thereweremanywithdrawals for any reason from the longer
of the three studies (Aaron 2007) and in this study the withdrawal
rate was significantly higher in the tiotropium + placebo group
(47%) than in the tiotropium + LABA/ICS group (26%) (OR
0.38; 95% CI 0.23 to 0.62). The two shorter studies had fewer
withdrawals and they were more evenly distributed between the
tiotropium + LABA/ICS groups (Cazzola 2007, 3/13% andWelte
2009 8/9% in the tiotropium + LABA/ICS /tiotropium + placebo
group respectively). BothAaron2007 andWelte 2009 reported the
breakdown of the reasons for withdrawals, which showed that the
difference between the number withdrawing due to adverse events
(OR 0.92; 95% CI 0.46 to 1.83) was not statistically significant,
whereas the difference between the number withdrawing due to
lack of efficacywas significantly higher in the tiotropium + placebo
group than in the tiotropium + LABA/ICS group (OR 0.36; 95%
CI 0.22 to 0.59).
Tiotropium plus LABA/ICS versus LABA/ICS plus
placebo
Cazzola 2007 was the only eligible study identified comparing
tiotropium + LABA/ICS versus LABA/ICS + placebo (60 pa-
tients). The study reported results for the following outcomes of
interest for this review:
Primary outcome: mortality (all causes)
Cazzola 2007 reported zero serious adverse events and therefore
we assumed there were no deaths during the study.
Secondary outcome: forced expiratory volume in one
second (FEV1)
Tiotropium in combination with LABA/ICS improves FEV1 sig-
nificantly compared to LABA/ICS + placebo (MD 0.05; 95% CI
0.00 to 0.09), but the mean difference and confidence interval
were below the minimal clinically important difference of 100
to140 mL.
Secondary outcome: serious adverse events (non-fatal)
There were no serious adverse events in either intervention group.
Secondary outcome: adverse events
There were more adverse events in the tiotropium + LABA/ICS
group (15/30) than in the tiotropium + placebo group (8/30), but
the confidence interval was wide, due to small numbers of events
(OR 2.75; 95% CI 0.93 to 8.10).
Secondary outcome: withdrawal
There were fewer withdrawals in the tiotropium + LABA/ICS
group (1/30) than the tiotropium + placebo group (4/30), but the
number of events was small and not statistically significant (OR
0.22; 95% CI 0.02 to 2.14).
D I S C U S S I O N
Summary of main results
This systematic review set out to investigate the long-term (≥ three
months) effects of tiotropium in combination with LABA/ICS
compared to either LABA/ICS alone or tiotropium alone, for the
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treatment of COPD. Three randomised, double-blind, placebo-
controlled trials with 1021 participants were identified. All three
studied the effects of tiotropium in combination with LABA/ICS
compared to tiotropium alone, whereas only one of these studies
(60 participants) also looked at tiotropium in combination with
LABA/ICS compared to LABA/ICS (Cazzola 2007).
Tiotropium plus LABA/ICS versus tiotropium plus
placebo
The results from this review did not show any significant difference
between tiotropium + LABA/ICS and tiotropium + placebo in
mortality, the number of patients suffering from pneumonia, or
having one or more hospital admissions. However, the individual
study authors’ analyses of rate ratios showed a significant benefit of
tiotropium + LABA/ICS treatment compared to tiotropium alone
for the total number of hospital admissions (Aaron 2007), and for
exacerbations leading to hospitalisations or emergency room visits
(Aaron 2007; Welte 2009). We did not pool data for number of
patients suffering one or more exacerbations due to heterogeneity.
This review did find that tiotropium in combination with LABA/
ICS significantly improved FEV1 for COPD patients compared to
treatment with tiotropium alone. However, the mean increase was
below what may be considered a clinically significant difference
(100 to140mL). Similarlymean change in quality of life scoreswas
lower than a four unit change (which is considered to be clinically
significant), although the change, favouring tiotropium + LABA/
ICS treatment, was statistically significant. One included study
reported significantly more patients with a clinically significant
improvement in their quality of life score in the tiotropium +
LABA/ICS group than in the group on tiotropium alone (Welte
2009).
The effect of tiotropium + LABA/ICS combination treatment on
mortality and pneumonia remains uncertain due to the low num-
bers of events, which were small in comparison to the high num-
bers of withdrawals and participants lost to follow-up. Also, Aaron
2007 reported only pneumonia leading to mechanical ventilation
or death as the study took place at a time when the authors were
unaware of any association of pneumonia with the use of inhaled
corticosteroids.
Even though there was no significant difference in the number of
patients admitted to hospital due to exacerbations or all causes,
Aaron 2007 reported a significant difference in all cause hospital-
isation (rate ratio 0.67; 95% CI 0.45 to 0.99) and hospital admis-
sions due to exacerbation (rate ratio 0.53; 95% CI 0.33 to 0.86)
when data were analysed as rate ratios. Similarly Welte 2009 re-
ported significantly lower numbers of hospitalisations/ emergency
room visits for exacerbations in the tiotropium+ LABA/ICS group
compared to the tiotropium + placebo group (rate ratio 0.35; 95%
CI 0.16 to 0.78). There are many ways to analyse exacerbation/
hospitalisation rates and all have different advantages and disad-
vantages. Looking at the number of patients suffering one or more
exacerbation will show the direction of the intervention effect but
it does not give any information about potential difference in ex-
acerbation frequency in the same patient and it does not take into
account variable lengths of study time (Keene 2008). Using the
rate ratio of exacerbations is more informative about exacerbation
rates in the trial populations, but the various different statistical
methods used to calculate this means that one has to be careful
when combining/pooling the results from different trials. There
are many possible reasons for the discrepancies in statistical sig-
nificance between the results when they are analysed in different
ways. There may be a difference in power between the methods,
and chance could lead to a significant difference using one method
and a non-significant difference using another.
Welte 2009 showed significantly fewer exacerbations in the group
treated with tiotropium + LABA/ICS compared to the group
treated with tiotropium + placebo (OR 0.38; 95% CI 0.25 to
0.57), whereas Aaron 2007 showed no significant difference be-
tween the two groups (OR 0.85; 95% CI 0.65 to 1.11). The dif-
ference between the study results was large enough to introduce
considerable heterogeneity, and the two study results were there-
fore not combined. The reason for the heterogeneity is unknown
but there are considerable differences between the two studies
which could have an influence including; type of combination
treatment, length of study, baseline risk, and notably definition of
exacerbation. Aaron 2007 defined exacerbation as a worsening of
COPD leading to treatment with systemic steroids and/or antibi-
otics. Welte 2009 defined exacerbation as a worsening of COPD
leading to treatment with systemic steroids and/or hospitalisation/
emergency room visits.
Treatment with tiotropium + LABA/ICS led to a greater im-
provement in health-related quality of life than treatment with
tiotropium alone. However, the mean difference in quality of life
score was below the limit of clinical significance (less than four
units) although the difference between the intervention groups
was statistically significant (MD -2.49; 95% CI -4.04 to -0.94).
However, Welte 2009 showed a statistically significant difference
in the number of patients who had a clinically significant improve-
ment in quality of life score (tiotropium + LABA/ICS 49.5%,
tiotropium + placebo 40.0%, P = 0.016), whereas there was no
significant difference in the number whose quality of life score de-
teriorated (tiotropium + LABA/ICS 27.6%, tiotropium + placebo
29.7%). This illustrates that a small mean difference does not
rule out the possibility of additional combination treatment being
of benefit in some patients. This possibility does not only cover
health-related quality of life but also changes in FEV1.
The difference in serious adverse events between the intervention
groups was not statistically significant. The numbers were low in
total and compared to the number of withdrawals and participants
lost to follow-up. The withdrawals from the studies did not seem
to be linked to adverse events but to the efficacy of the treatment.
LABA/ICS plus tiotropium versus LABA/ICS plus
15Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic
obstructive pulmonary disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
placebo
The one pilot study looking at the effect of LABA/ICS +
tiotropium versus LABA/ICS + placebo showed a significantly
larger improvement in FEV1 with tiotropium + LABA/ICS treat-
ment compared to LABA/ICS treatment (Cazzola 2007), how-
ever the mean difference in FEV1 was not clinically significant. All
other outcomes of interest were either not studied, had no events
or did not achieve a statistically significant difference.
Overall completeness and applicability of
evidence
For the comparison of the benefits and risks of treatment with
tiotropium + LABA/ICS versus LABA/ICS one smaller study was
eligible (Cazzola 2007), which did not look at or report any of
the primary outcomes specified in this review except for mortality.
Therefore there was little applicable evidence for this comparison
from this review.
For the comparison of the benefits and risks of treatment with
tiotropium + LABA/ICS versus tiotropium, the total number of
patients in the included studies was insufficient and the differences
between the studies too many (type of combination treatment,
study length, definition of outcomes) to show any relevant statis-
tically significant difference for several of the outcomes.
One limitation of the included studies was their duration. Two
out of three studies (Cazzola 2007; Welte 2009) were only three
months and the third was one year (Aaron 2007). A minimum of
six months’ treatment would be advisable to be able to judge long-
term benefits and risks of the studied interventions. However such
a criteria also limits the number of eligible studies and leads to
larger numbers of withdrawals in the included studies, which in
turn will lead to an increased risk of bias.
There were too few eligible studies to break down the result in
subgroups of disease severity or type of combination therapy.
Quality of the evidence
Aaron 2007 andWelte 2009 were of good methodological quality.
However, long COPD trials (longer than six months) like Aaron
2007, which are essential to study long-term efficacy and risks with
COPD interventions, will inevitably suffer from large numbers
of withdrawals (Welsh 2010). Aaron 2007 did address this issue
by sensitivity analyses for their primary outcome; COPD exac-
erbation. The authors assumed that all patients who were lost to
follow-up in both intervention groups either did not have an ex-
acerbation, had an exacerbation or had exacerbations at the same
rate as those who continued in the study. However, they did not
investigate the effect of the greatest possible difference between
the intervention groups; assuming that all patients lost to follow-
up in one intervention groups had an exacerbation and that all
patients lost to follow-up in the other intervention group did not
have an exacerbation. Even though the issue of withdrawals was
addressed, it could introduce bias.
Cazzola 2007 could not provide additional information regarding
allocation concealment, blinding, funding and withdrawals and
therefore introduced an unknown risk of bias. However, a sen-
sitivity analysis removing the Cazzola 2007 data from the FEV1
analysis did not change the outcome substantially.
Potential biases in the review process
The issue of large and/or uneven numbers of withdrawals, as men-
tioned above (Quality of the evidence), will, even if addressed,
possibly introduce bias as there is no consensus on how to handle
participants for whom no data are available.
We analysed available data as specified in the protocol. However,
we did expand the review question from the protocol to include
the comparison of tiotropium + LABA/ICS versus LABA/ICS +
placebo. We also highlighted rate ratios for hospital admissions
and percentage of patients with a clinically significant change in
health-related quality of life reported by the authors although this
was not specified in Measures of treatment effect.
Agreements and disagreements with other
studies or reviews
No reviews looking at the long-term efficacy and adverse effects
of tiotropium + LABA/ICS treatment compared to tiotropium
or LABA/ICS have been identified. However, a systematic re-
view looking at LABA/ICS combination treatment compared to
placebo has shown that combination treatment significantly re-
duces mortality and exacerbation rates, and improves lung func-
tion (Nannini 2007). LABA/ICS also increases the risk of pneu-
monia compared with placebo. Tiotropium on its own has been
shown to reduce COPD exacerbations and related hospitalisa-
tions compared to placebo (Barr 2005). Tiotropium also improves
health-related quality of life among patients with moderate and
severe disease. Although no conclusion has been drawn regarding
the effect of tiotropium on mortality rates and change in FEV1
(Barr 2005), these reviews may give an indication of the treatment
efficacy that can be anticipated from treatment with tiotropium +
LABA/ICS compared to tiotropium alone.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The total patient number from the included studies was insuffi-
cient and the differences between the studies too great to draw any
general conclusions from the results regarding the long-term ef-
fects and risks of tiotropium + LABA/ICS treatment. The relative
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efficacy and safety of tiotropium + LABA/ICS treatment therefore
remains uncertain.
Implications for research
Additional large, long-term randomised controlled trials are re-
quired to reduce the uncertainty about the efficacy and risks of
tiotropium in combination with LABA/ICS for COPD patients.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aaron 2007
Methods Design: A randomised, double-blind, placebo-controlled, parallel group trial from Oc-
tober 2003 to January 2006. The trial included 27 Canadian medical centres; 20 centres
were academic hospital-based pulmonary clinics, 5 were community-based pulmonary
clinics, and 2 were community-based primary care clinics
Participants Population: 449 adults with a clinical history of moderate or severe COPD as defined
by ATS and GOLD guidelines
Baseline Characteristics: Mean age 68 years. COPD severity moderate to severe with
mean FEV1 predicted of 39%. 44% women.
Inclusion Criteria: At least 1 exacerbation of COPD that required treatment with sys-
temic steroids or antibiotics within the 12 months before randomisation; age older than
35 years; a history of 10 pack-years or more of cigarette smoking; documented chronic
airflow obstruction, with an FEV1/FVC ratio less than 0.70 and a post-bronchodilator
FEV1 less than 65% of the predicted value.
Exclusion Criteria: History of physician-diagnosed asthma before 40 years of age; his-
tory of physician-diagnosed chronic congestive heart failure with known persistent severe
left ventricular dysfunction; those receiving oral prednisone; those with a known hy-
persensitivity or intolerance to tiotropium, salmeterol, or fluticasone-salmeterol; history
of severe glaucoma or severe urinary tract obstruction, previous lung transplantation or
lung volume reduction surgery, or diffuse bilateral bronchiectasis; and those who were
pregnant or were breastfeeding
Interventions 1. Tiotropium + salmeterol + fluticasone: tiotropium (Spiriva, Handihaler (Boehringer
Ingelheim Pharma, Ingelheim, Germany)), 18 g once daily, plus fluticasone-salmeterol
(Advair (GlaxoSmithKline)), 250/25 g/puff, 2 puffs twice daily
2. Tiotropium + salmeterol: tiotropium, 18 g once daily, plus salmeterol (Serevent (Glax-
oSmithKline, Research Triangle Park, North Carolina)), 25 g/puff, 2 puffs twice daily
3. Tiotropium + placebo: tiotropium, 18g once daily, plus placebo inhaler, 2 puffs twice
daily
Outcomes Primary: Proportion of patients with one or more exacerbation of COPD
Secondary: Mean number of COPD exacerbations per patient-year; the total number of
exacerbations that resulted in urgent visits to a healthcare provider or emergency depart-
ment; the number of hospitalisations for COPD; the total number of hospitalisations
for all causes; changes in health-related quality of life, dyspnoea, lung function
Notes Co-medication: All study patients were provided with inhaled albuterol and were in-
structed to use it when necessary to relieve symptoms. Any treatment with inhaled cor-
ticosteroids, long-acting 2-agonists, and anticholinergics that the patient may have been
using before entry was discontinued on entry into the study. Therapy with other respira-
tory medications, such as oxygen, antileukotrienes, and methylxanthines, was continued
in all patient groups
Risk of bias
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Aaron 2007 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation was done through central
allocation of a randomisation schedule that
was prepared from a computer-generated
random listing of the 3 treatment alloca-
tions, blocked in variable blocks of 9 or 12
and stratified by site
Allocation concealment? Yes Neither research staff nor patients were
aware of the treatment assignment before
or after randomisation
Blinding?
All outcomes
Yes The metered-dose inhalers containing
placebo, salmeterol, and fluticasone-salme-
terol were identical in taste and appear-
ance, and they were enclosed in identical
tamper-proof blinding devices. The medi-
cation canisters within the blinding devices
were stripped of any identifying labelling
Incomplete outcome data addressed?
All outcomes
Unclear The number of people who stopped drug
therapy was high, with large variations be-
tween the groups (74 (47%) tiotropium
+ placebo and 37 (26%) tiotropium +
LABA/ICS comb.). However, the num-
ber of people who did not complete the
trial was lower, although there was still
large variations between the groups (30
(19%) tiotropium + placebo and 15 (10%)
tiotropium + LABA/ICS comb.). The issue
of incomplete data was however addressed
by sensitivity analyses of the data com-
prising alternative assumptions for patients
who prematurely withdrew from treatment
Free of selective reporting? Yes Results for all listed primary and secondary
outcomes were reported
Cazzola 2007
Methods Design: A randomised, double-blind, double-dummy, parallel group trial over 12 weeks
Participants Population: 90 patients with well-controlled COPD.
Baseline Characteristics: Mean age 66 years. COPD severity severe to very severe with
mean FEV1 predicted of 38%. 11% women.
Inclusion Criteria: Baseline FEV1 of less than 50% of predicted, and a post-bron-
chodilator FEV1/FVC < 70% following salbutamol 400 mg according to the GOLD
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Cazzola 2007 (Continued)
criteria of severity
Exclusion Criteria: Current evidence of asthma as primary diagnosis; unstable respira-
tory disease requiring oral/parenteral corticosteroids within 4 weeks prior to beginning
the study; upper or lower respiratory tract infection within 4 weeks of the screening visit;
unstable angina or unstable arrhythmias; concurrent use of medications that affected
COPD; and evidence of alcohol abuse
Interventions 1. LABA/ICS comb. + placebo: FSC 500/50 mg Diskus, 1 inhalation twice daily +
placebo Handihaler 1 inhalation once-daily
2. Tiotropium + placebo: Tiotropium 18 mg Handihaler, 1 inhalation once-daily +
placebo Diskus, 1 inhalation twice daily
3. Tiotropium + LABA/ICS comb: FSC 500/50 mg Diskus, 1 inhalation twice daily +
tiotropium 18 mg Handihaler, 1 inhalation once-daily
Outcomes Mean change from baseline in predose FEV1 after 3-month treatment, change from
baseline in VAS score assessing dyspnoea and in supplemental salbutamol
Notes Run-in: Patients entered a 2-week run-in period during which their regular treatment
for COPD (all were under regular treatment with a long-acting beta2-agonist and an
inhaled corticosteroid, many (81 out of 90) with also theophylline) was stopped with
the exception of stable regimens of theophylline (no change in dose for 1 month prior
to screening) and they received salbutamol for relief of breakthrough symptoms. Use of
all other inhaled or oral bronchodilators, systemic corticosteroids, ipratropium bromide,
oxitropium bromide, or leukotriene modifiers was prohibited
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Patients were randomised to receive FSC,
tiotropium or their combination by a com-
puter-generated list. Randomisation was
performed in blocks of 9
Allocation concealment? Unclear No details
Blinding?
All outcomes
Unclear No details
Incomplete outcome data addressed?
All outcomes
Yes Dropout rate 10%
Free of selective reporting? Yes Results for all listed outcomes were re-
ported
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Welte 2009
Methods Design:A randomised, double-blind, parallel-group,multicenter trial fromMay 2007 to
June 2008. The trial included 102 centres in 9 countries: Australia (10 centres), Canada
(16), France (12), Germany (12), Hungary (13), Poland (10), Slovakia (13), Spain (6)
and Sweden (10)
Participants Population: 660 patients with COPD eligible for LABA/ICS combination therapy, with
a pre-bronchodilator FEV1 not exceeding 50% of the predicted normal value and a
history of exacerbations requiring systemic steroids and/or antibiotics, were studied
Baseline Characteristics: Mean age 62 years. COPD severity, moderate, severe to very
severe with mean FEV1 predicted of 38%. 25% women.
Inclusion Criteria: Patients with COPD eligible for inhaled corticosteroid/long-acting
beta2-agonist (LABA/ICS) combination therapy aged≥ 40years, with a clinical diagnosis
of COPD and symptoms for at least 2 years, at least one COPD exacerbation in the
previous 12 months requiring systemic steroids and/or antibiotics, current or previous
smokers with a smoking history of≥10 pack-years, forced expiratory volume in 1 second
(FEV1) ≤ 50% of predicted normal value and
FEV1 / vital capacity < 70% pre-dose.
Exclusion Criteria: Worsening of COPD during run-in or within 4 weeks prior to visit
2 requiring hospitalisation, a course of oral and/or inhaled steroids and/or antibiotics,
use of ICS within 2 weeks prior to visit 2, use of oral/parenteral glucocorticosteroids
within 4 weeks prior to visit 2, a history of asthma or any significant disease/disorder
which, in the opinion of the investigator, may put the patient at risk or influence results
Interventions 1. Tiotropium + LABA/ICS comb: Tiotropium (Handihaler) 18 mg once daily + budes-
onide/formoterol (Symbicort Turbuhaler; AstraZeneca, Lund, Sweden) 320/9 mg one
inhalation twice daily
2. Tiotropium + placebo: Tiotropium 18 mg once daily + placebo (identicalTurbuhaler)
twice daily
Outcomes Primary: Change in predose FEV1 from randomisation (Week 0) to the full treatment
period (mean FEV1 at 1, 6, and 12 wk of treatment)
Secondary: Pre- and post-dose spirometry measurements (predose FVC and inspiratory
capacity and post-treatment FEV1 (5 and 60 min), forced vital capacity (5 and 60 min)
, and inspiratory capacity (60 min)) and the St. George’s Respiratory Questionnaire for
COPD (SGRQ-C)
Notes Run-in: Before entering the study, patients stopped their LABA and ICS medication
(4 weeks and 2 weeks prior to run-in, respectively). During the 2-week run-in period,
all patients used tiotropium (Spiriva HandiHaler, Boehringer Ingelheim, Germany) 18
µg once daily. Terbutaline 0.5 mg/inhalation (Bricanyl® Turbuhaler®, AstraZeneca,
Lund, Sweden) was used as needed for symptom relief during the run-in period
Co-medication: Terbutaline 0.5 mg/inhalation (Bricanyl® Turbuhaler®, AstraZeneca,
Lund, Sweden) was used as needed for symptom relief during the treatment period in
both treatment arms
Risk of bias
Item Authors’ judgement Description
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Welte 2009 (Continued)
Adequate sequence generation? Yes Randomisation codes were sequentially as-
signed to patients from a computer-gener-
ated list at AstraZeneca R&D, Lund, Swe-
den, as they became eligible
Allocation concealment? Yes The investigators were provided with a
blinded randomisation code for each pa-
tient. Both clinicians and patients were
blinded to treatment until completion of
the study.
Blinding?
All outcomes
Yes Treatment assignment was concealed as ac-
tive and placebo Turbuhalers were of iden-
tical appearance
Incomplete outcome data addressed?
All outcomes
Yes The dropout rates were 9% in the
tiotropium + placebo and 8% in the
tiotropium + LABA/ICS comb group re-
spectively
Free of selective reporting? Yes All collected data reported.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ando 2008 Effects of tiotropium alone versus salmeterol/fluticasone combination
Bateman 2008 Effects of tiotropium alone versus salmeterol/fluticasone combination
Biscione 2009 4 weeks of treatment
Golabi 2006 Effects of tiotropium alone versus salmeterol/fluticasone combination
Hara 2007 Effects of tiotropium alone versus salmeterol/fluticasone combination
Perng 2006 1 month of treatment and crossover design
Petroianni 2008 Effects of tiotropium treatment alone versus formoterol treatment alone
Singh 2008 14 days of treatment and of crossover design
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Characteristics of studies awaiting assessment [ordered by study ID]
Fang 2008
Methods Design: randomised, parallel-group, 12 months’ treatment
Participants 126 patients (M/F: 92/34) with COPD
Interventions salmeterol/fluticasone (50/250 µg) twice daily and tiotropium 18 µg once daily (n = 33, M/F: 23/10)
salmeterol/fluticasone (50/250 µg) twice daily (n = 32, M/F: 24/8)
tiotropium 18 µg once daily (n = 32, M/F: 23/9)
blank control group (n = 29, M/F: 22/7), patients in this group did not receive any inhaled anticholinergic drugs,
long-acting beta2 agonists or glucocorticoid therapy
Outcomes Symptoms, health status, use of rescue medication, frequency of exacerbations, and FEV1
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. tiotropium plus LABA/ICS combination versus tiotropium plus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality (all cause) 3 1021 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.88 [0.57, 6.23]
2 Hospital admission (all causes) 2 961 Odds Ratio (M-H, Fixed, 95% CI) 0.84 [0.53, 1.33]
3 Hospital admission
(exacerbation)
2 961 Odds Ratio (M-H, Fixed, 95% CI) 0.66 [0.39, 1.13]
4 Exacerbation 2 Odds Ratio (M-H, Random, 95% CI) Totals not selected
5 Pneumonia 2 961 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.35 [0.31, 5.99]
6 Quality of life SGRQ scale 2 Mean Difference (Fixed, 95% CI) Subtotals only
6.1 Quality of life 3-5 months
mean difference + 1 yr SE
2 Mean Difference (Fixed, 95% CI) -2.49 [-4.04, -0.94]
6.2 Quality of life 1 yr 1 Mean Difference (Fixed, 95% CI) -4.1 [-7.22, -0.98]
7 FEV1 3 Mean Difference (Fixed, 95% CI) Subtotals only
7.1 FEV1 3-5 months mean
difference + 1yr SE
3 Mean Difference (Fixed, 95% CI) 0.06 [0.04, 0.08]
7.2 FEV1 1 yr 1 Mean Difference (Fixed, 95% CI) Not estimable
8 Serious adverse event (non-fatal) 3 1021 Odds Ratio (M-H, Fixed, 95% CI) 0.60 [0.29, 1.25]
9 Adverse event 3 1021 Odds Ratio (M-H, Fixed, 95% CI) 1.12 [0.85, 1.49]
10 Withdrawal 3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 Total number of subjects
withdrawn
3 1021 Odds Ratio (M-H, Fixed, 95% CI) 0.54 [0.38, 0.77]
10.2 Due to adverse events 2 961 Odds Ratio (M-H, Fixed, 95% CI) 0.92 [0.46, 1.83]
10.3 Due to lack of efficacy 2 961 Odds Ratio (M-H, Fixed, 95% CI) 0.36 [0.22, 0.59]
11 Hospital admission (all causes)
rate ratio
1 Risk Ratio (Fixed, 95% CI) Totals not selected
12 Hospital admission
(exacerbation) rate ratio
2 Risk Ratio (Fixed, 95% CI) Subtotals only
13 Clinically relevant change in
quality of life
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 2. LABA/ICS combination plus tiotropium versus LABA/ICS combination plus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FEV1 GIV 1 Mean Difference (Fixed, 95% CI) Totals not selected
2 Adverse event 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Withdrawal 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4 FEV1 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 tiotropium plus LABA/ICS combination versus tiotropium plus placebo,
Outcome 1 Mortality (all cause).
Review: Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary
disease
Comparison: 1 tiotropium plus LABA/ICS combination versus tiotropium plus placebo
Outcome: 1 Mortality (all cause)
Study or subgroup tiotropium+LABA/ICS tiotropium+placebo Peto Odds Ratio Peto Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Aaron 2007 6/145 4/156 1.63 [ 0.46, 5.74 ]
Cazzola 2007 0/30 0/30 0.0 [ 0.0, 0.0 ]
Welte 2009 1/329 0/331 7.43 [ 0.15, 374.66 ]
Total (95% CI) 504 517 1.88 [ 0.57, 6.23 ]
Total events: 7 (tiotropium+LABA/ICS), 4 (tiotropium+placebo)
Heterogeneity: Chi2 = 0.52, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours triple treatment Favours tiotropium
Analysis 1.2. Comparison 1 tiotropium plus LABA/ICS combination versus tiotropium plus placebo,
Outcome 2 Hospital admission (all causes).
Review: Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary
disease
Comparison: 1 tiotropium plus LABA/ICS combination versus tiotropium plus placebo
Outcome: 2 Hospital admission (all causes)
Study or subgroup tiotropium+LABA/ICS tiotropium+placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aaron 2007 32/145 36/156 66.6 % 0.94 [ 0.55, 1.62 ]
Welte 2009 9/329 14/331 33.4 % 0.64 [ 0.27, 1.49 ]
Total (95% CI) 474 487 100.0 % 0.84 [ 0.53, 1.33 ]
Total events: 41 (tiotropium+LABA/ICS), 50 (tiotropium+placebo)
Heterogeneity: Chi2 = 0.58, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
0.2 0.5 1 2 5
Favours triple treatment Favours tiotropium
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Analysis 1.3. Comparison 1 tiotropium plus LABA/ICS combination versus tiotropium plus placebo,
Outcome 3 Hospital admission (exacerbation).
Review: Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary
disease
Comparison: 1 tiotropium plus LABA/ICS combination versus tiotropium plus placebo
Outcome: 3 Hospital admission (exacerbation)
Study or subgroup tiotropium+LABA/ICS tiotropium+placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aaron 2007 20/145 28/156 70.3 % 0.73 [ 0.39, 1.37 ]
Welte 2009 5/329 10/331 29.7 % 0.50 [ 0.17, 1.47 ]
Total (95% CI) 474 487 100.0 % 0.66 [ 0.39, 1.13 ]
Total events: 25 (tiotropium+LABA/ICS), 38 (tiotropium+placebo)
Heterogeneity: Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.50 (P = 0.13)
0.1 0.2 0.5 1 2 5 10
Favours triple treatment Favours tiotropium
Analysis 1.4. Comparison 1 tiotropium plus LABA/ICS combination versus tiotropium plus placebo,
Outcome 4 Exacerbation.
Review: Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary
disease
Comparison: 1 tiotropium plus LABA/ICS combination versus tiotropium plus placebo
Outcome: 4 Exacerbation
Study or subgroup tiotropium+LABA/ICS tiotropium+placebo Odds Ratio Odds Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Aaron 2007 87/145 98/156 0.89 [ 0.56, 1.41 ]
Welte 2009 25/329 61/331 0.36 [ 0.22, 0.60 ]
0.2 0.5 1 2 5
Favours triple treatment Favours tiotropium
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Analysis 1.5. Comparison 1 tiotropium plus LABA/ICS combination versus tiotropium plus placebo,
Outcome 5 Pneumonia.
Review: Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary
disease
Comparison: 1 tiotropium plus LABA/ICS combination versus tiotropium plus placebo
Outcome: 5 Pneumonia
Study or subgroup tiotropium+LABA/ICS tiotropium+placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Aaron 2007 1/145 0/156 14.4 % 7.97 [ 0.16, 402.79 ]
Welte 2009 3/329 3/331 85.6 % 1.01 [ 0.20, 5.02 ]
Total (95% CI) 474 487 100.0 % 1.35 [ 0.31, 5.99 ]
Total events: 4 (tiotropium+LABA/ICS), 3 (tiotropium+placebo)
Heterogeneity: Chi2 = 0.92, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours triple treatment Favours tiotropium
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Analysis 1.6. Comparison 1 tiotropium plus LABA/ICS combination versus tiotropium plus placebo,
Outcome 6 Quality of life SGRQ scale.
Review: Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary
disease
Comparison: 1 tiotropium plus LABA/ICS combination versus tiotropium plus placebo
Outcome: 6 Quality of life SGRQ scale
Study or subgroup Mean Difference (SE) Mean Difference Weight Mean Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 Quality of life 3-5 months mean difference + 1 yr SE
Aaron 2007 -3.07 (1.592) 24.7 % -3.07 [ -6.19, 0.05 ]
Welte 2009 -2.3 (0.911) 75.3 % -2.30 [ -4.09, -0.51 ]
Subtotal (95% CI) 100.0 % -2.49 [ -4.04, -0.94 ]
Heterogeneity: Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 3.15 (P = 0.0016)
2 Quality of life 1 yr
Aaron 2007 -4.1 (1.592) 100.0 % -4.10 [ -7.22, -0.98 ]
Subtotal (95% CI) 100.0 % -4.10 [ -7.22, -0.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.58 (P = 0.010)
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Analysis 1.7. Comparison 1 tiotropium plus LABA/ICS combination versus tiotropium plus placebo,
Outcome 7 FEV1.
Review: Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary
disease
Comparison: 1 tiotropium plus LABA/ICS combination versus tiotropium plus placebo
Outcome: 7 FEV1
Study or subgroup Mean Difference (SE) Mean Difference Weight Mean Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 FEV1 3-5 months mean difference + 1yr SE
Aaron 2007 0.071 (0.03) 16.6 % 0.07 [ 0.01, 0.13 ]
Cazzola 2007 0.05 (0.018) 46.1 % 0.05 [ 0.01, 0.09 ]
Welte 2009 0.065 (0.02) 37.3 % 0.07 [ 0.03, 0.10 ]
Subtotal (95% CI) 100.0 % 0.06 [ 0.04, 0.08 ]
Heterogeneity: Chi2 = 0.50, df = 2 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 4.84 (P < 0.00001)
2 FEV1 1 yr
Aaron 2007 0.059 (0.03) 100.0 % 0.06 [ 0.00, 0.12 ]
Subtotal (95% CI) 100.0 % 0.06 [ 0.00, 0.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.97 (P = 0.049)
-0.1 -0.05 0 0.05 0.1
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Analysis 1.8. Comparison 1 tiotropium plus LABA/ICS combination versus tiotropium plus placebo,
Outcome 8 Serious adverse event (non-fatal).
Review: Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary
disease
Comparison: 1 tiotropium plus LABA/ICS combination versus tiotropium plus placebo
Outcome: 8 Serious adverse event (non-fatal)
Study or subgroup tiotropium+LABA/ICS tiotropium+placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aaron 2007 3/145 6/156 0.53 [ 0.13, 2.15 ]
Cazzola 2007 0/30 0/30 0.0 [ 0.0, 0.0 ]
Welte 2009 9/329 14/331 0.64 [ 0.27, 1.49 ]
Total (95% CI) 504 517 0.60 [ 0.29, 1.25 ]
Total events: 12 (tiotropium+LABA/ICS), 20 (tiotropium+placebo)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours triple treatment Favours tiotropium
Analysis 1.9. Comparison 1 tiotropium plus LABA/ICS combination versus tiotropium plus placebo,
Outcome 9 Adverse event.
Review: Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary
disease
Comparison: 1 tiotropium plus LABA/ICS combination versus tiotropium plus placebo
Outcome: 9 Adverse event
Study or subgroup tiotropium+LABA/ICS tiotropium+placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aaron 2007 44/145 37/156 26.7 % 1.40 [ 0.84, 2.34 ]
Cazzola 2007 15/30 13/30 7.0 % 1.31 [ 0.47, 3.61 ]
Welte 2009 81/329 82/331 66.3 % 0.99 [ 0.70, 1.41 ]
Total (95% CI) 504 517 100.0 % 1.12 [ 0.85, 1.49 ]
Total events: 140 (tiotropium+LABA/ICS), 132 (tiotropium+placebo)
Heterogeneity: Chi2 = 1.28, df = 2 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
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Analysis 1.10. Comparison 1 tiotropium plus LABA/ICS combination versus tiotropium plus placebo,
Outcome 10 Withdrawal.
Review: Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary
disease
Comparison: 1 tiotropium plus LABA/ICS combination versus tiotropium plus placebo
Outcome: 10 Withdrawal
Study or subgroup tiotropium+LABA/ICS tiotropium+placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Total number of subjects withdrawn
Aaron 2007 37/145 74/156 63.5 % 0.38 [ 0.23, 0.62 ]
Cazzola 2007 1/30 4/30 4.6 % 0.22 [ 0.02, 2.14 ]
Welte 2009 26/329 29/331 31.9 % 0.89 [ 0.51, 1.55 ]
Subtotal (95% CI) 504 517 100.0 % 0.54 [ 0.38, 0.77 ]
Total events: 64 (tiotropium+LABA/ICS), 107 (tiotropium+placebo)
Heterogeneity: Chi2 = 5.78, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 3.43 (P = 0.00060)
2 Due to adverse events
Aaron 2007 8/145 8/156 42.8 % 1.08 [ 0.39, 2.96 ]
Welte 2009 8/329 10/331 57.2 % 0.80 [ 0.31, 2.05 ]
Subtotal (95% CI) 474 487 100.0 % 0.92 [ 0.46, 1.83 ]
Total events: 16 (tiotropium+LABA/ICS), 18 (tiotropium+placebo)
Heterogeneity: Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
3 Due to lack of efficacy
Aaron 2007 25/145 58/156 79.7 % 0.35 [ 0.21, 0.60 ]
Welte 2009 5/329 12/331 20.3 % 0.41 [ 0.14, 1.18 ]
Subtotal (95% CI) 474 487 100.0 % 0.36 [ 0.22, 0.59 ]
Total events: 30 (tiotropium+LABA/ICS), 70 (tiotropium+placebo)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 4.12 (P = 0.000038)
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Analysis 1.11. Comparison 1 tiotropium plus LABA/ICS combination versus tiotropium plus placebo,
Outcome 11 Hospital admission (all causes) rate ratio.
Review: Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary
disease
Comparison: 1 tiotropium plus LABA/ICS combination versus tiotropium plus placebo
Outcome: 11 Hospital admission (all causes) rate ratio
Study or subgroup log [Risk Ratio] Risk Ratio Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Aaron 2007 -0.4 (0.2) 0.67 [ 0.45, 0.99 ]
0.2 0.5 1 2 5
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Analysis 1.12. Comparison 1 tiotropium plus LABA/ICS combination versus tiotropium plus placebo,
Outcome 12 Hospital admission (exacerbation) rate ratio.
Review: Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary
disease
Comparison: 1 tiotropium plus LABA/ICS combination versus tiotropium plus placebo
Outcome: 12 Hospital admission (exacerbation) rate ratio
Study or subgroup log [Risk Ratio] Risk Ratio Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Aaron 2007 -0.63 (0.24) 0.53 [ 0.33, 0.85 ]
Welte 2009 -1.05 (0.4) 0.35 [ 0.16, 0.77 ]
Subtotal (95% CI) 0.0 [ 0.0, 0.0 ]
Heterogeneity: Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 tiotropium plus LABA/ICS combination versus tiotropium plus placebo,
Outcome 13 Clinically relevant change in quality of life.
Review: Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary
disease
Comparison: 1 tiotropium plus LABA/ICS combination versus tiotropium plus placebo
Outcome: 13 Clinically relevant change in quality of life
Study or subgroup tiotropium+LABA/ICS tiotropium+placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Welte 2009 163/329 132/331 1.48 [ 1.09, 2.02 ]
0.5 0.7 1 1.5 2
Favours tiotropium Favours triple treatment
Analysis 2.1. Comparison 2 LABA/ICS combination plus tiotropium versus LABA/ICS combination plus
placebo, Outcome 1 FEV1 GIV.
Review: Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary
disease
Comparison: 2 LABA/ICS combination plus tiotropium versus LABA/ICS combination plus placebo
Outcome: 1 FEV1 GIV
Study or subgroup Mean Difference (SE) Mean Difference Mean Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Cazzola 2007 0.046 (0.023) 0.05 [ 0.00, 0.09 ]
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Analysis 2.2. Comparison 2 LABA/ICS combination plus tiotropium versus LABA/ICS combination plus
placebo, Outcome 2 Adverse event.
Review: Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary
disease
Comparison: 2 LABA/ICS combination plus tiotropium versus LABA/ICS combination plus placebo
Outcome: 2 Adverse event
Study or subgroup LABA/ICS+tiotropium LABA/ICS+placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cazzola 2007 15/30 8/30 2.75 [ 0.93, 8.10 ]
0.01 0.1 1 10 100
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Analysis 2.3. Comparison 2 LABA/ICS combination plus tiotropium versus LABA/ICS combination plus
placebo, Outcome 3 Withdrawal.
Review: Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary
disease
Comparison: 2 LABA/ICS combination plus tiotropium versus LABA/ICS combination plus placebo
Outcome: 3 Withdrawal
Study or subgroup LABA/ICS+tiotropium LABA/ICS+placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cazzola 2007 1/30 4/30 0.22 [ 0.02, 2.14 ]
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Analysis 2.4. Comparison 2 LABA/ICS combination plus tiotropium versus LABA/ICS combination plus
placebo, Outcome 4 FEV1.
Review: Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary
disease
Comparison: 2 LABA/ICS combination plus tiotropium versus LABA/ICS combination plus placebo
Outcome: 4 FEV1
Study or subgroup LABA/ICS+tiotropium LABA/ICS+placebo Mean Difference Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Cazzola 2007 29 0.186 (0.089) 26 0.14 (0.078) 0.05 [ 0.00, 0.09 ]
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We included the comparison of treatment with tiotropium plus LABA/ICS versus LABA/ICS. In response to a peer review comment
we changed the health-related quality of life outcome from secondary to primary.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Inhalation; Adrenergic beta-2 Receptor Agonists [∗administration & dosage]; Bronchodilator Agents [∗administration
& dosage]; Drug Therapy, Combination [methods]; Glucocorticoids [∗administration & dosage]; Pulmonary Disease, Chronic Ob-
structive [∗drug therapy; mortality]; Randomized Controlled Trials as Topic; Scopolamine Derivatives [administration & dosage]
MeSH check words
Humans
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